China Pharmaceutical University (CPU), situated in the historical and cultural city of Nanjing, is one of the “211 project” key universities affiliated to the Ministry of Education of China. It has been known for its long history and its leadership role in China’s pharmaceutical academic field. The University was founded in 1936 as China’s first independent four-year National College of Pharmacy and the first public institution for higher pharmaceutical education in China.

CPU provides a wide variety of disciplines including Sciences, Medicine, Engineering, Economics, Management, Arts and Law. The first-level discipline of Pharmacy was enlisted as National Key Discipline. In 2015’s ESI statistics, our pharmacology and toxicology, chemistry, as well as clinical pharmacy programs ranked the world’s top 1%. The publications in pharmacology and toxicology ranked top of the nation. CPU offers 25 bachelor’s degree programs, 5 associate (polytechnic) programs, 24 research-oriented doctoral degree programs under the two first-level disciplines of Pharmacy and Traditional Chinese Pharmacy, 36 research-oriented master’s degree programs under 5 first-level disciplines, 23 disciplines open to post-doctoral research scholars under the two first-level disciplines of Pharmacy and Traditional Chinese Pharmacy, as well as 5 professional degree programs at the master’s level. 

The University promotes innovation in research and aims to develop novel medicines for public health. It has founded 18 key labs including The State Key Laboratory of Natural Medicines and key labs at provincial or ministerial levels, engineering technical centers, innovative platforms. The university has established academic collaboration with overseas universities and institutions in over 40 countries and regions. During 2011-2015 the university has undertaken 26 major projects for the nation’s Innovative New Drug projects and was endowed with 178 million Yuan funding, being No.1 among all universities nationwide. Our researchers won two 2nd Prizes of National Science and Technology Progress Award. 2 new drugs were national certified and 6 new drugs were approved for clinical research, and 410 patents were attained and 3919 SCI-indexed articles were published.